Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of bemnifosbuvir in high-risk outpatients with COVID-19
PACTR202304814474622Phase 3Recruiting
- Sponsor
- Atea Pharmaceuticals
- Start
- Nov 2022
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 3, randomised, double-blind trial in coronavirus disease 2019 (COVID-19) comparing Bemnifosbuvir with Placebo (2 arms). Primary endpoint: Hospitalization or death through Day 29. Started Nov 2022; status: recruiting.
02
Drugs
bemnifosbuvir
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on PACTR202304814474622.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202304814474622.